STICH3C: Rationale and Study Protocol
Circulation: Cardiovascular Interventions · 2023-08 · 16 (8)
DOI: 10.1161/circinterventions.122.012527 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Circulation: Cardiovascular Interventions, 2023-08. Verfasst von Stephen E Fremes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (S.E.F., D.V., H.C.W.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Percutaneous Coronary Intervention, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: CIHR.
Abstract (Originalsprache)
BACKGROUND: Coronary artery bypass grafting (CABG) is the recommended mode of revascularization in patients with ischemic left ventricular dysfunction (iLVSD) and multivessel disease. However, contemporary percutaneous coronary intervention (PCI) outcomes have improved with the integration of novel technologies and refinement of revascularization strategies, and PCI is often used in clinical practice in this population. There is a lack of evidence from randomized trials comparing contemporary state-of-the-art PCI versus CABG for the treatment of iLVSD and multivessel disease. This was the impetus for the STICH3C trial (Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy), described here. METHODS: The STICH3C trial is a prospective, unblinded, international, multicenter trial with an expected sample size of 754 participants from ≈45 centers. Patients with multivessel/left main coronary artery disease and iLVSD with left ventricular ejection fraction ≤40% considered by the local Heart Team appropriate for and amenable to revascularization by both modes of revascularization will be randomized in a 1:1 ratio to state-of-the-art PCI or CABG. RESULTS: The primary end point is the composite of death from any cause, stroke, spontaneous myocardial infarction, urgent repeat revascularization, or heart failure readmission, summarized as a time-to-event outcome. The key hierarchical end point is time to death and frequency of hospitalizations for heart failure. The key safety outcome is a composite of major adverse events. Disease-specific quality-of-life and health economics measures will be compared between groups. Participants will be followed for a median of 5 years, with a minimum follow-up of 4 years. CONCLUSIONS: STICH3C will directly inform patients, clinicians, and international practice guidelines about the efficacy and safety of CABG versus PCI in patients with iLVSD. The results will provide novel and broad evidence, including clinical events, health status, and economic assessments, to guide care for patients with iLVSD and severe coronary artery disease. REGISTRATION: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT05427370.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (S.E.F., D.V., H.C.W.).
- Montreal Heart Institute, University of Montreal, Quebec, Canada (G.M.-G., E.M.J., J.-L.R.).
- Department of Cardiothoracic Surgery (M.F.L.G.), Weill Cornell Medicine, New York City, NY.
- Centre d'excellence sur le partenariat avec les patients et le public, Montreal, Quebec, Canada (S.B.).
- Division of Health Informatics (R.M.C.), Weill Cornell Medicine, New York City, NY.
- Division of Cardiac Surgery, University of Ottawa Heart Institute, Ontario, Canada (M.R.).
ORCID-Profile: Stephen E Fremes, Guillaume Marquis-Gravel, Mario F L Gaudino, Sylvain Bédard, Ruth Masterson Creber, Marc Ruel, Dominique Vervoort, Harindra C Wijeysundera
Förderung
- CIHR
Zitieren
APA
Fremes, S. E., Marquis-Gravel, G., Gaudino, M. F. L., Jolicoeur, E. M., Bédard, S., Masterson Creber, R., Ruel, M., Vervoort, D., Wijeysundera, H. C., Farkouh, M. E., Rouleau, J. L., & STICH3C Study Investigators (2023). STICH3C: Rationale and Study Protocol. Circulation: Cardiovascular Interventions, 16(8). https://doi.org/10.1161/circinterventions.122.012527
Vancouver
Fremes SE, Marquis-Gravel G, Gaudino MFL, Jolicoeur EM, Bédard S, Masterson Creber R, et al. STICH3C: Rationale and Study Protocol. Circulation: Cardiovascular Interventions. 2023;16(8). doi:10.1161/circinterventions.122.012527
BibTeX
@article{Fremes2023,
author = {Fremes, Stephen E and Marquis-Gravel, Guillaume and Gaudino, Mario F L and Jolicoeur, E Marc and Bédard, Sylvain and Masterson Creber, Ruth and Ruel, Marc and Vervoort, Dominique and Wijeysundera, Harindra C and Farkouh, Michael E and Rouleau, Jean-Lucien and STICH3C Study Investigators, STICH3C Study Investigators},
title = {STICH3C: Rationale and Study Protocol},
journal = {Circulation: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {8},
doi = {10.1161/circinterventions.122.012527}
}
EUVIMED